Skip to main content

Advertisement

SpringerLink
Log in

Clinical Practice and Research in Cardio-Oncology: Finding the “Rosetta Stone” for Establishing Program Excellence in Cardio-oncology

  • Review Article
  • Published:
Journal of Cardiovascular Translational Research Aims and scope Submit manuscript

Abstract

The burgeoning field of cardio-oncology (C-O) is now necessary for the delivery of excellent care for patients with cancer. Many factors have contributed to this increasing population of cancer survivors or those being treated with novel and targeted cancer therapies. There is a tremendous need to provide outstanding cardiovascular (CV) care for these patients; however, current medical literature actually provides a paucity of guidance. C-O therefore provides a novel opportunity for clinical, translational, and basic research to advance patient care. This review aims to be a primer for cardio-oncologists on how to develop a vibrant and comprehensive C-O program, use practical tools to assist in the construction of C-O services, and to proactively incorporate translational and clinical research into the training of future leaders as well as enhance clinical care.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Lenihan, D. (2017). Cardio-oncology: What is the best practice we can all strive for? International Journal of Cardiology, 241, 393–394.

    PubMed  Google Scholar 

  2. Lenihan, D. J., Cardinale, D., & Cipolla, C. M. (2010). The compelling need for a cardiology and oncology partnership and the birth of the International CardiOncology Society. Progress in Cardiovascular Diseases, 53, 88–93.

    PubMed  Google Scholar 

  3. Lancellotti, P., Suter, T. M., Lopez-Fernandez, T., et al. (2019). Cardio-oncology services: Rationale, organization, and implementation. European Heart Journal, 40, 1756–1763.

    PubMed  Google Scholar 

  4. Bhatt, D. L. (2019). Birth and maturation of cardio-oncology. JACC: CardioOncology, 1, 3.

    Google Scholar 

  5. Hayek, S. S., Ganatra, S., Lenneman, C., et al. (2019). Preparing the cardiovascular workforce to care for oncology patients: JACC review topic of the week. Journal of the American College of Cardiology, 73, 2226–2235.

    PubMed  PubMed Central  Google Scholar 

  6. Howlader N. K. M., Neyman N., et al. (eds) (2011). SEER Cancer Statistics Review, 1975–2008. National Cancer Institute, Bethesda, MD:seer.cancer.gov/csr/1975_2008/.

  7. Miller, K. D., Siegel, R. L., Lin, C. C., et al. (2016). Cancer treatment and survivorship statistics, 2016. CA: a Cancer Journal for Clinicians, 66, 271–289.

    Google Scholar 

  8. Sturgeon, K. M., Deng, L., Bluethmann, S. M., et al. (2019). A population-based study of cardiovascular disease mortality risk in US cancer patients. European Heart Journal, 40, 3889–3897.

    PubMed  PubMed Central  Google Scholar 

  9. Campia, U., Moslehi, J. J., Amiri-Kordestani, L., et al. (2019). Cardio-oncology: vascular and metabolic perspectives: A scientific statement from the American Heart Association. Circulation, 139, e579–e602.

    PubMed  PubMed Central  Google Scholar 

  10. Kenigsberg, B., Wellstein, A., & Barac, A. (2018). Left ventricular dysfunction in cancer treatment: Is it relevant? JACC Heart failure, 6, 87–95.

    PubMed  Google Scholar 

  11. Cornell, R. F., Ky, B., Weiss, B. M., et al. (2019). Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma. Journal of Clinical Oncology, JCO1900231.

  12. Ball, S., Ghosh, R. K., Wongsaengsak, S., et al. (2019). Cardiovascular toxicities of immune checkpoint inhibitors: JACC review topic of the week. Journal of the American College of Cardiology, 74, 1714–1727.

    CAS  PubMed  Google Scholar 

  13. Ganatra, S., Parikh, R., & Neilan, T. G. (2019). Cardiotoxicity of immune therapy. Cardiology Clinics, 37, 385–397.

    PubMed  Google Scholar 

  14. Armenian, S. H., Xu, L., Ky, B., et al. (2016). Cardiovascular disease among survivors of adult-onset cancer: A community-based retrospective cohort study. Journal of Clinical Oncology, 34, 1122–1130.

    CAS  PubMed  PubMed Central  Google Scholar 

  15. Valentine, C. M. (2018). Tackling the quadruple aim: Helping cardiovascular professionals find work-life balance. Journal of the American College of Cardiology, 71, 1707–1709.

    PubMed  Google Scholar 

  16. Cornell, R. F., Ky, B., Weiss, B. M., et al. (2019). Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma. Journal of Clinical Oncology, 37, 1946–1955.

    CAS  PubMed  Google Scholar 

  17. Jovenaux, L., Cautela, J., Resseguier, N., et al. (2017). Practices in management of cancer treatment-related cardiovascular toxicity: A cardio-oncology survey. International Journal of Cardiology, 241, 387–392.

    PubMed  Google Scholar 

  18. Naidoo, J., Zhang, J., Lipson, E. J., et al. (2019). A multidisciplinary toxicity team for Cancer immunotherapy-related adverse events. Journal of the National Comprehensive Cancer Network, 17, 712–720.

    PubMed  Google Scholar 

  19. Lefrak, E. A., Pitha, J., Rosenheim, S., & Gottlieb, J. A. (1973). A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer, 32, 302–314.

    CAS  PubMed  Google Scholar 

  20. Sawyer, D. B. (2013). Anthracyclines and heart failure. The New England Journal of Medicine, 368, 1154–1156.

    CAS  PubMed  Google Scholar 

  21. Slamon, D. J., Leyland-Jones, B., Shak, S., et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. The New England Journal of Medicine, 344, 783–792.

    CAS  PubMed  Google Scholar 

  22. Moslehi, J. J. (2016). Cardiovascular toxic effects of targeted Cancer therapies. The New England Journal of Medicine, 375, 1457–1467.

    CAS  PubMed  Google Scholar 

  23. Armenian, S. H., Lacchetti, C., Barac, A., et al. (2017). Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. Journal of Clinical Oncology, 35, 893–911.

    PubMed  Google Scholar 

  24. Alvi, R. M., Frigault, M. J., Fradley, M. G., et al. (2019). Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T). Journal of the American College of Cardiology, 74, 3099–3108.

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Guha, A., Armanious, M., & Fradley, M. G. (2019). Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities. Trends in Cardiovascular Medicine, 29, 29–39.

    CAS  PubMed  Google Scholar 

  26. Curigliano, G., Lenihan, D., Fradley, M., et al. (2020). Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Annals of Oncology, 31, 171–190.

    CAS  PubMed  Google Scholar 

  27. Koene, R. J., Prizment, A. E., Blaes, A., & Konety, S. H. (2016). Shared risk factors in cardiovascular disease and cancer. Circulation, 133, 1104–1114.

    PubMed  PubMed Central  Google Scholar 

  28. Armenian, S. H., Armstrong, G. T., Aune, G., et al. (2018). Cardiovascular disease in survivors of childhood cancer: Insights into epidemiology, pathophysiology, and prevention. Journal of Clinical Oncology, 36, 2135–2144.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Decker, I., Goodman, S. A., Phillips, S. E., Lenihan, D. J., & Cornell, R. F. (2017). The six-minute walk test is a valuable measure of functional change following chemotherapy for AL (light-chain) cardiac amyloidosis. British Journal of Haematology, 177, 481–483.

    PubMed  Google Scholar 

  30. Ness, K. K., Plana, J. C., Joshi, V. M., et al. (2020). Exercise intolerance, mortality, and organ system impairment in adult survivors of childhood cancer. Journal of Clinical Oncology, 38, 29–42.

    PubMed  Google Scholar 

  31. Pareek, N., Cevallos, J., Moliner, P., et al. (2018). Activity and outcomes of a cardio-oncology service in the United Kingdom-a five-year experience. European Journal of Heart Failure, 20, 1721–1731.

    PubMed  Google Scholar 

  32. Arnold, A. M., & Biga, C. (2019). Implementing a cardio-oncology Center of Excellence: Nuts and bolts, including coding and billing. Cardiology Clinics, 37, 545–557.

    PubMed  Google Scholar 

  33. Unger, J. M., Moseley, A., Symington, B., Chavez-MacGregor, M., Ramsey, S. D., & Hershman, D. L. (2018). Geographic distribution and survival outcomes for rural patients with Cancer treated in clinical trials. JAMA Network Open, 1, e181235.

    PubMed  PubMed Central  Google Scholar 

  34. Orlando, J. F., Beard, M., & Kumar, S. (2019). Systematic review of patient and caregivers’ satisfaction with telehealth videoconferencing as a mode of service delivery in managing patients' health. PLoS One, 14, e0221848.

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Fradley, M. G., Brown, A. C., Shields, B., et al. (2017). Developing a comprehensive cardio-oncology program at a cancer institute: The Moffitt Cancer Center experience. Oncology Reviews, 11, 340.

    PubMed  PubMed Central  Google Scholar 

  36. Lyons, P. G., Klaus, J., McEvoy, C. A., Westervelt, P., Gage, B. F., & Kollef, M. H. (2019). Factors associated with clinical deterioration among patients hospitalized on the wards at a tertiary cancer hospital. Journal of Oncology Practice/ American Society of Clinical Oncology, 15, e652–e665.

    Google Scholar 

  37. Totzeck, M., Schuler, M., Stuschke, M., Heusch, G., & Rassaf, T. (2019). Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease. International Journal of Cardiology, 280, 163–175.

    PubMed  Google Scholar 

  38. Dang, C., Guo, H., Najita, J., et al. (2016). Cardiac outcomes of patients receiving adjuvant weekly paclitaxel and Trastuzumab for node-negative, ERBB2-positive breast Cancer. JAMA Oncology, 2, 29–36.

    PubMed  PubMed Central  Google Scholar 

  39. Pituskin, E., Haykowsky, M., McNeely, M., Mackey, J., Chua, N., & Paterson, I. (2016). Rationale and design of the multidisciplinary team IntervenTion in cArdio-oNcology study (TITAN). BMC Cancer, 16, 733.

    PubMed  PubMed Central  Google Scholar 

  40. Pituskin, E., Paterson, I., Cox-Kennett, N., Rothe, D., Perri, M., & Becher, H. (2017). The role of cardio-oncology in the interprofessional care of adult patients receiving cancer therapy. Seminars in Oncology Nursing, 33, 384–392.

    PubMed  Google Scholar 

  41. Parent, S., Pituskin, E., & Paterson, D. I. (2016). The cardio-oncology program: A multidisciplinary approach to the care of cancer patients with cardiovascular disease. The Canadian Journal of Cardiology, 32, 847–851.

    PubMed  Google Scholar 

  42. Kappel, C., Rushton, M., Johnson, C., et al. (2019). Clinical experience of patients referred to a multidisciplinary cardio-oncology clinic: An observational cohort study. Current Oncology, 26, e322–e327.

    CAS  PubMed  PubMed Central  Google Scholar 

  43. Sundlöf, D., Patel, B., Schadler, K., Biggs, R., Silverstein Fadlon, C., Corotto, P., Tolay, S., Nadeem, A., Gupta, R., & Ahmad, N. (2019). Development of a cardio-oncology program in a community hospital. JACC: CardioOncology, 1, 310–313.

    PubMed  PubMed Central  Google Scholar 

  44. Gentry, S., & Badrinath, P. (2017). Defining health in the era of value-based care: Lessons from England of relevance to other health systems. Cureus, 9, e1079.

    PubMed  PubMed Central  Google Scholar 

  45. Miller, A. P., Handberg, E. M., & Rodgers, G. P. (2018). It takes a team to deliver optimal cardiovascular care. Journal of the American College of Cardiology, 72, 948–951.

    PubMed  Google Scholar 

  46. Barac, A., Murtagh, G., Carver, J. R., et al. (2015). Cardiovascular health of patients with Cancer and Cancer survivors: A roadmap to the next level. Journal of the American College of Cardiology, 65, 2739–2746.

    PubMed  PubMed Central  Google Scholar 

  47. Okwuosa, T. M., & Barac, A. (2015). Burgeoning cardio-oncology programs: Challenges and opportunities for early career cardiologists/faculty directors. Journal of the American College of Cardiology, 66, 1193–1197.

    PubMed  Google Scholar 

  48. Lynce, F., Barac, A., Geng, X., et al. (2019). Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: The SAFE-HEaRt study. Breast Cancer Research and Treatment, 175, 595–603.

    CAS  PubMed  PubMed Central  Google Scholar 

  49. Bureau USC. Health insurance coverage in the United States: 2017. 2019.

  50. Health Insurance Coverage of the Total Population. 2017.

  51. Kline, R., Adelson, K., Kirshner, J. J., et al. (2017). The oncology care model: Perspectives from the centers for Medicare & Medicaid services and participating oncology practices in academia and the community. American Society of Clinical Oncology educational book American Society of Clinical Oncology Annual Meeting, 37, 460–466.

    PubMed  Google Scholar 

  52. Caffrey, M., & Inserro, A. (2018). Azar announces mandatory oncology payment model is coming. American Journal Managed Care.

  53. Lenihan, D. J., Hartlage, G., DeCara, J., et al. (2016). Cardio-oncology training: A proposal from the International Cardioncology Society and Canadian Cardiac Oncology Network for a new multidisciplinary specialty. Journal of Cardiac Failure, 22, 465–471.

    PubMed  Google Scholar 

  54. Armenian, S. H., Lacchetti, C., Barac, A., et al. (2016). Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. Journal of Clinical Oncology, 35, 893–911. https://doi.org/10.1200/JCO.2016.70.5400

  55. Gillebert, T. C., Brooks, N., Fontes-Carvalho, R., et al. (2013). ESC core curriculum for the general cardiologist (2013). European Heart Journal, 34, 2381–2411.

    PubMed  Google Scholar 

  56. Lenihan, D. J., Fradley, M., Dent, S., Brezden-Masley, C., Carver, J., Filho, R., Neilan, T., Blaes, A., Melloni, C., Herrmann, J., Armenian, S., Thavendiranathan, P., Armstrong, G., Ky, B., & Hajjar, L. (2019). Proceedings from the global cardio-oncology summit: The top 10 priorities to actualize for CardioOncology. JACC: CardioOncology, 1, 256–272.

    PubMed  PubMed Central  Google Scholar 

  57. Ganatra, S., & Hayek, S. S. (2018). Cardio-oncology for GenNext: A missing piece of the training puzzle. Journal of the American College of Cardiology, 71, 2977–2981.

    PubMed  Google Scholar 

  58. McCune, J. S. (2018). Rapid advances in immunotherapy to treat Cancer. Clinical Pharmacology and Therapeutics, 103, 540–544.

    PubMed  Google Scholar 

  59. Moslehi, J., Fujiwara, K., & Guzik, T. (2019). Cardio-oncology: A novel platform for basic and translational cardiovascular investigation driven by clinical need. Cardiovascular Research, 115, 819–823.

    CAS  PubMed  Google Scholar 

  60. Shelburne, N., Adhikari, B., Brell, J., et al. (2014). Cancer treatment-related cardiotoxicity: Current state of knowledge and future research priorities. Journal of the National Cancer Institute, 106. https://doi.org/10.1093/jnci/dju232

  61. Banerjee, S., Califano, R., Corral, J., et al. (2017). Professional burnout in European young oncologists: Results of the European Society for Medical Oncology (ESMO) Young Oncologists Committee Burnout Survey. Annals of Oncology, 28, 1590–1596.

    CAS  PubMed  PubMed Central  Google Scholar 

  62. Sulpher, J., Mathur, S., Lenihan, D., et al. (2015). An international survey of health care providers involved in the management of cancer patients exposed to cardiotoxic therapy. Journal of Oncology, 2015, 391848.

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, PA, USA

    Srinath Adusumalli, Sameed M. Khatana & Rupal O’Quinn

  2. Cardio-Oncology Center of Excellence, Division of Cardiovascular Medicine, Washington University in St Louis, 660 South Euclid Avenue, Campus box 8086, St. Louis, MO, 63110-1093, USA

    Jose Alvarez-Cardona, Joshua D. Mitchell & Daniel J. Lenihan

  3. Department of Medicine, Division of Hematology/Oncology, University of Minnesota, Minneapolis, MN, USA

    Anne H. Blaes

  4. The International Cardio-Oncology Society, Tampa, FL, USA

    Stephen J. Casselli

Authors
  1. Srinath Adusumalli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jose Alvarez-Cardona
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sameed M. Khatana
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Joshua D. Mitchell
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Anne H. Blaes
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Stephen J. Casselli
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Rupal O’Quinn
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Daniel J. Lenihan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel J. Lenihan.

Ethics declarations

Conflict of Interest

The authors report no relevant conflicts for this manuscript with the exception of DL who has received research funding from Myocardial Solutions, Inc. and has modest consultant arrangements with Roche, Bristol-Myers Squibb, and Pfizer.

Ethical approval

This article does not contain any studies with human participants performed by any of the authors.

Additional information

Associate Editor Ana Barac oversaw the review of this article

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Highlights

• Cardio-oncology (C-O) has become a major clinical need for patients with cancer.

• The necessary elements to develop a C-O service include communication, collaboration, monitoring, and documentation.

• The added value of C-O services include improved time on effective cancer therapy, preventing cardiotoxicity, and enhanced clinical outcomes of mortality and morbidity.

• Participation in research is a necessary component for the adequate development and continuous improvement of clinical care.

Electronic supplementary material

ESM 1

(DOCX 33.8 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Adusumalli, S., Alvarez-Cardona, J., Khatana, S.M. et al. Clinical Practice and Research in Cardio-Oncology: Finding the “Rosetta Stone” for Establishing Program Excellence in Cardio-oncology. J. of Cardiovasc. Trans. Res. 13, 495–505 (2020). https://doi.org/10.1007/s12265-020-10010-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12265-020-10010-x

Keywords

Search

Navigation